Helsinki heart study: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 27: | Line 27: | ||
| '''Condition'''||Primary dyslipidemia | | '''Condition'''||Primary dyslipidemia | ||
|- | |- | ||
| '''Intervention'''|| | | '''Intervention'''||Gemfibrozil <br> Placebo | ||
|- | |- | ||
| '''Population Size'''||4081 subjects | | '''Population Size'''||4081 subjects | ||
| Line 37: | Line 37: | ||
==Publications== | ==Publications== | ||
===Results=== | ===Results=== | ||
The HHS revealed that the treatment with | The HHS revealed that the treatment with [[gemfibrozil]] led to an increase in [[HDL]] cholesterol and a decrease in non-HDL cholesterol and [[triglyceride]]s as compared to placebo. Compared to placebo, [[gemfibrozil]] decreased the [[incidence]] of coronary heart disease by 32% without any change in the rate of death.<ref name="pmid3313041">{{cite journal| author=Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al.| title=Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. | journal=N Engl J Med | year= 1987 | volume= 317 | issue= 20 | pages= 1237-45 | pmid=3313041 | doi=10.1056/NEJM198711123172001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3313041 }} </ref> | ||
==References== | ==References== | ||
Revision as of 02:10, 19 August 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Helsinki heart study On the Web |
|
American Roentgen Ray Society Images of Helsinki heart study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
The Helsinki Heart Study (HHS) is a randomized double-blind trial that assessed the primary cardiovascular preventive effect of elevation in HDL and decrease in non-HDL cholesterol with gemfibrozil.
Study Description
| Study Description | |
| Study Design | |
| Allocation | Randomized |
| Endpoint | Coronary heart disease |
| Masking | Double blind |
| Study Details | |
| Primary Purpose | Prevention |
| Condition | Primary dyslipidemia |
| Intervention | Gemfibrozil Placebo |
| Population Size | 4081 subjects |
The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number #.
Publications
Results
The HHS revealed that the treatment with gemfibrozil led to an increase in HDL cholesterol and a decrease in non-HDL cholesterol and triglycerides as compared to placebo. Compared to placebo, gemfibrozil decreased the incidence of coronary heart disease by 32% without any change in the rate of death.[1]
References
- ↑ Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P; et al. (1987). "Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease". N Engl J Med. 317 (20): 1237–45. doi:10.1056/NEJM198711123172001. PMID 3313041.